Domestic political situation keeps German sales in check
This article was originally published in Clinica
Executive Summary
German medical technology sales rose by 2% in 2005, an improvement on the 1.5% growth seen in 2004, but still far behind the international average, which, as in 2004, was 7%. So said industry association BVMed this week, reporting on the sales and profits of its 210 member companies. They seemed to perform marginally better in Germany than those of fellow industry association Spectaris, however; its member companies recorded a 2% drop in sales to the German market in 2005 (see Clinica No 1193, p 5).
You may also be interested in...
Can Organovo Leverage Its Solid Phase II Data In MASH?
Cash-limited Organovo has an FXR agonist showing competitive efficacy and tolerability in MASH, but may need a partner to move forward in that disease as it may be prioritizing its IBD program.
Cullinan Changes Tracks, Moving Lymphoma Bispecific Into Autoimmune
The company will discontinue its trial of the CD19-directed bispecific CLN-978 in NHL and develop it in inflammatory diseases, where it could have an edge over CAR-Ts.
Interview: Theradaptive To Enter Clinical Trial For Spinal Fusion Gel
Theradaptive, which makes a device-biologic combination product to help speed bone healing, recently got authorization to start human trials from the US FDA. Medtech Insight spoke to CEO Luis Alvarez about the company’s past, present and future.